Search Criteria: Cancer Studies;
A study testing the combination of dasatinib or imatinib to chemotherapy treatment with blinatumomab for children, adolescents, and young adults with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL)
The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. (IRB#: IRB_00191773)
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT. (IRB#: IRB_00189859)
Cancer Stories Shaping Outcomes Can Your Cellphone Be a Compassionate Listener?
This study is looking at cancer patient voices, actions and body language using computer measurements of behavior via video-recorded answers to questions on your smartphone device using a free app. This research is important because it may help us discover and understand unknown factors that impact cancer treatment outcomes. (IRB#: IRB_00143135)
Digital Storytelling Study for Young Cancer Survivors
The purpose of this study is to understand the experiences of people ages 15 to 39 years old who face cancer. The study wants to learn what supports improve the quality of life when going through cancer and after the treatment is completed. Being in the study requires completing two 5-minute surveys and participating in digital storytelling by being in a private online chat group for 12 weeks. Each week participants will respond to 2-3 questions about health related to the quality of life. Participants will be paid for being in the study. (IRB#: IRB_00172717)
FIREFLY-1
The description and purpose of the study drug is to research the use of an investigational product labeled NA- IP (DAY 101- formerly TAK-580/MLN2480) to treat Low-Grade Glioma and other advanced solid tumors in pediatric and age-of-majority participants (IRB#: IRB_00138633)
HCI-Total Cancer Care Study
This study is a partnership between participants, health care providers, and researchers. Our aim is to better understand what causes cancer and to find better ways to prevent, detect, and treat cancer more successfully while also supporting your family. This study is an opportunity to contribute samples and information that will be used to accelerate cancer research and improve patient care. Participants like you are vital to our success. The study also offers access to a broader set of clinical trials and new treatments through our partnership with other leading cancer centers nationally. There is no cost to be in this study. No matter what you decide, it won't change the relationship with your health care providers to affect the quality of your care. (IRB#: IRB_00089989)
Improving Health Insurance Literacy for Young Adult Cancer Survivors
Health insurance can be difficult for young adults with cancer to find answers to questions about their health insurance plan. This studys purpose is to help young adult cancer survivors understand their health insurance and costs. People in this study are required to complete 3 online surveys over 12 months. Each survey will take about 20 minutes. Participants will be paid for completing each activity. Some participants will receive a digital informational booklet about health insurance while other participants will receive this booklet and also complete 4 health insurance support sessions with a navigator. Sessions will be completed on Zoom and last about 45 minutes. (IRB#: IRB_00164028)
Long-Term Follow-Up of Patients Who Received Lentiviral-Based CAR-T Cell Therapy
People with specific types of cancer such as leukemia and lymphomas may receive Lentiviral-Based CAR-T Cell Therapy. This is to help improve the symptoms of this disease. Research is needed to learn the long-term safety and effectiveness of the therapy. The information we gain may provide further guidance to patients, doctors, and researchers. (IRB#: IRB_00079262)
Motivation for People to Quit Smoking
This study wants to learn what motivates people who smoke to try quitting. The study wants to understand how certain factors, such as emotions and stress, make people feel motivated to quit smoking and whether they try quitting. Participants will have one online virtual visit at the beginning of the study. Participation also requires answering a 3-minute survey on the smartphone app 2 times per day for 28 days. Being in the study will last about 1 month. The surveys will ask participants about feelings, experiences, emotions, smoking, and whether they tried to quit that day. (IRB#: IRB_00190436)
Needs Assessment of Young Adult Rural Cancer Caregivers
Young adult rural cancer caregivers experience unique challenges. These include mental health, financial hardship, and unmet social needs. This study wants to better understand the needs and challenges of young adult rural cancer caregivers. The information will help develop and test interventions to improve young adult rural cancer caregiver experiences. Being in the study requires completing a 15 to 20-minute online survey. Participants will also complete a 30 to 45-minute online video interview. Participants will be paid for being in the study. (IRB#: IRB_00180551)
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB) A COG Groupwide Phase 3 Study
This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor. The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Topotecan is in a class of medications called topoisomerase I inhibitors. It works by interfering with tumor cell DNA which kills them. Giving topotecan in addition to standard IVADo and IVA chemotherapy regimens may shrink the cancer as well as or better than the standard therapy or could decrease the chance the tumor spreads while causing fewer side effects. (IRB#: IRB_00189967)
Researching Biopsies of People with Aggressive Cutaneous Lymphoma
Aggressive cutaneous lymphoma is a rare and life-threatening cancer with limited treatment options. Participants will not receive treatment/medication for the condition in this study. This study will observe participants with aggressive lymphomas and their previously collected biopsies to learn more about lymphomas and their response to different treatments. Being in the study requires participants to share medical records and previous biopsies of skin tissue to be tested, shared with other researchers, and stored for future research. (IRB#: IRB_00143860)
Testing the Drug Cabozantinib in Pediatric Cancers
Cabozantinib is an approved drug shown to reduce tumor growth. This study will test the drug to treat types of pediatric cancers. The study wants to see if the drug will help people with the pediatric cancers and is safe. People in the study will keep a medical diary and take Cabozantinib as a swallowed tablet to see how the tumor responds. If the tumor becomes smaller or remains the same size and/or if no tumor forms participants may continue taking the study drug for up to 52 weeks. Study participation lasts about 64 weeks. Medical tests will be done to track the health of participants. (IRB#: IRB_00165978)
Testing the Drug Nivolumab for Pediatric Patients with Recurrent or Progressive High-Grade Glioma
Recurrent or progressive high-grade glioma (HGG) is a brain tumor that rapidly grows and spreads within the brain or spinal cord. This study will test a drug called nivolumab to treat pediatric patients with HGG. This study wants to see if the drug will help people with the disease and is safe. Participants will receive nivolumab for about 2 weeks before a scheduled surgery to remove the tumor and then again after the surgery. Study participation includes 2 years of treatment and about 5 years of follow-up. Medical tests and surveys will be done to track the health of participants. (IRB#: IRB_00142607)
Testing the Drug ONC201 for Pediatric Patients with Diffuse Midline Gliomas
Diffuse Midline Gliomas is a fast-growing pediatric cancer that forms in the brain. This study will test a drug called ONC201, alone or in combination with other drugs or radiation, to treat the disease. This study wants to see if the drug will help people with the disease and is safe. Participants will receive either ONC201 only or ONC201 in combination with another drug or radiation. Study participation includes about 2 years of treatment and 5 years of follow-up. Medical tests and surveys will be done to track the health of participants. (IRB#: IRB_00149140)
Testing the Treatment of Donor Cell Transplants for Children and Young Adults with Severe Myeloid Leukemia
This study is testing the treatment with Natural Killer cells from a donor to a patient, which may lower the chance that a blood disease severe myeloid leukemia will come back after a haploidentical (half-matched) transplant (moving cells from a donor to a patient). The study wants to see if the treatment will help people with severe myeloid leukemia. People in the study will receive Natural Killer cells from a central line placed in the body, most likely the chest. A central line is a tube that allows medications, medical tests, and transfusions to occur. Transfusion is a way to move blood from a donor to a patient. Being in the study requires attending in-person study visits at a clinic for about 2 years. Medical tests will be done to track the health of participants. (IRB#: IRB_00152764)
Tobacco cessation among tobacco and marijuana co-users
Tobacco is related to cancer risk. Most attempts to quit are unsuccessful. Many people who use tobacco also use marijuana. Using the two substances together may impact whether tobacco quit attempts are successful. This study will provide information about factors that influence the use of tobacco and marijuana. This information we learn may aid future patients who would like to quit using tobacco. (IRB#: IRB_00168877)
Ultraviolet Ray Prevention for Children
Melanoma is the 6th most common type of skin cancer in the United States. The just-in-time intervention (JITAI) application (app) is a tool used on a cell phone. The tool can help children and adults know how much time in ultraviolet rays (UVL) from the sun. Research is needed to learn what children and adults think about using the JITAI app. We hope to reduce the time children spend in UVR, so sunburns occur less. (IRB#: IRB_00121617)